Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268974 | 0.86 | TDP1 (0.41) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4867872 | 0.85 | HPGDS (0.41) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4867115 | 0.85 | HPGDS (0.39) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4867189 | 0.84 | KDM4E (0.42) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL14268951 | 0.82 | CYP2E1 (0.46) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL14268956 | 0.75 | CYP2E1 (0.42) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13851862 | 0.75 | TDP1 (0.42) | KMT2AMEN1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL4873669 | 0.72 | MEN1 (0.43) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4871015 | 0.72 | TSHR (0.40) | ALDH1A1L3MBTL1MAPTTSHRRAB9A | |
| SCHEMBL14268976 | 0.72 | HTR1A (0.44) | KMT2AMEN1HPGDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7163924-B2 | Ketolide derivatives | CHIRON CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1618120-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050153905-A1 | Novel ketolide derivatives | CHIRON CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096823-A2 | NOVEL KETOLIDE DERIVATIVES | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | CYP2E1 323/4885CYP3A4 30/4885CYP2A6 57/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | CYP2E1 362/4885CYP3A4 120/4885CYP2A6 68/4885 |
| US-20050153905-A1 | Novel ketolide derivatives | KHK, CYP51A1, SI | CYP2E1 184/4885CYP3A4 73/4885CYP2A6 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.